Ligand Pharmaceuticals Incorporated (LGND) Investor Relations Documents

Ligand Pharmaceuticals Incorporated (LGND) investor relations documents from the company's IR site: 5 presentations, 35 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

Ligand Second Quarter 2026 Earnings Call: Ligand Pharmaceuticals reported Q2 2026 results featuring 32% royalty revenue growth and the acquisition of XOMA Royalty to expand its portfolio.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseLigand Reports Second Quarter 2026 Financial Results
2026-08-06Earnings deckLigand Second Quarter 2026 Earnings Call
2026-08-06Press releasePress Release
2026-07-23Press releaseLigand to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-14Press releaseDownload , Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty
2026-07-14Press releaseLigand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
2026-06-23Press releaseDownload , Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering, June 23, 2026, (opens in
2026-06-22Press releaseDownload , Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031, June 22, 2026, (open
2026-06-10Press releaseLigand Announces 2026 Investor Day in New York City
2026-05-27Press releaseDownload , Ligand to Participate in June Investor Conferences, May 27, 2026, (opens in new window)
2026-05-27Press releaseLigand to Participate in June Investor Conferences
2026-05-07Press releasePress Release
2026-05-07Earnings deckPresentation of Q1 2026, PDF file, (opens in new window)
2026-05-07Press releaseDownload (opens in new window)
2026-05-05Press releaseDownload , Ligand to Participate in May Investor Conferences, May 5, 2026, (opens in new window)
2026-05-05Press releaseLigand to Participate in May Investor Conferences
2026-04-27Press releaseDownload , Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a L
2026-04-27PresentationPRESENTATION Open Event Link, PDF file, April 27, 2026, (opens in new window)
2026-04-27Press releaseLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biop
2026-04-22Press releaseLigand to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-22Press releaseLigand to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-14Press releaseDownload , Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS, April 14,
2026-04-14Press releaseLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
2026-03-26Press releaseDownload , Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team, March 26, 2026, (o
2026-03-04Press releaseDownload , Ligand to Participate in March Investor Conferences, March 4, 2026, (opens in new window)
2026-02-26Press releaseDownload , Ligand Reports Fourth Quarter and Full Year 2025 Financial Results, February 26, 2026, (opens in new window)
2026-02-26Earnings deckPresentation Open Event Link, PDF file, February 26, 2026, (opens in new window)
2026-02-26Press releaseLigand Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-12Press releaseDownload , Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, February 12, 2026,
2026-02-12Press releaseLigand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2026-02-04Press releaseDownload , Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 4, 2026, (open
2025-12-09Press releaseLigand Hosts 2025 Investor Day and Introduces 2026 Guidance
2025-11-06Press releaseLigand Reports Third Quarter 2025 Financial Results and Raises Guidance
2025-11-05Earnings deckPresentation of Q3 2025 Press Release, (opens in new window)
2025-10-30Press releaseLigand to Participate in November Investor Conferences
2025-10-23Press releaseLigand to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-16Press releaseLigand to Host Investor Day on December 9, 2025
2025-10-09Press releaseLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Pati
2025-08-19Press releaseLigand to Participate in September Investor Conferences
2025-08-14Press releaseLigand Announces Closing of Convertible Senior Notes Offering

LGND overview · LGND earnings · LGND financials · LGND KPIs · LGND documents · LGND ownership · LGND peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.